학술논문
Aβ38 and Aβ43 do not differentiate between Alzheimer's disease and cerebral amyloid angiopathy.
Document Type
Article
Author
Dargvainiene, Justina; Jensen‐Kondering, Ulf; Bender, Benjamin; Berg, Daniela; Brüggemann, Norbert; Flüh, Charlotte; Markewitz, Robert; Neumann, Alexander; Röben, Benjamin; Röcken, Christoph; Royl, Georg; Schulte, Claudia; Wandinger, Klaus‐Peter; Weiler, Caroline; Margraf, Nils G.; Kuhlenbäumer, Gregor
Source
Subject
*CEREBRAL amyloid angiopathy
*ALZHEIMER'S disease
*CEREBROSPINAL fluid
*TAU proteins
*
*
*
Language
ISSN
2328-9503
Abstract
Differential diagnosis between Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA) using cerebrospinal fluid (CSF) biomarkers is challenging. A recent study suggested that the addition of Aβ38 and Aβ43 to a standard AD biomarker panel (Aβ40, Aβ42, t‐tau, p‐tau) to improve the differential diagnosis. We tested this hypothesis in an independent German cohort of CAA and AD patients and controls using the same analytical techniques. We found excellent discrimination between AD and controls and between CAA and controls, but not between AD and CAA. Adding Aβ38 and Aβ43 to the panel did not improve the discrimination between AD and CAA. [ABSTRACT FROM AUTHOR]